Ipsen's hopes for next-gen rare disease drug dashed by pivotal phase 2 fail
Ipsen's hopes for next-gen rare disease drug dashed by pivotal phase 2 fail
Body unavailable. Use the original source.
Ipsen's hopes for next-gen rare disease drug dashed by pivotal phase 2 fail
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.